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Abstract
Insulin-like growth factor (IGF)-1 is a key factor in bone
homeostasis and could be involved in bone tissue sclerosis as
observed in osteoarthritis (OA). Here, we compare the key
signaling pathways triggered in response to IGF-1 stimulation
between normal and OA osteoblasts (Obs). Primary Obs were
prepared from the subchondral bone of tibial plateaus of OA
patients undergoing knee replacement or from normal
individuals at autopsy. Phenotypic characterization of Obs was
evaluated with alkaline phosphatase and osteocalcin release.
The effect of IGF-1 on cell proliferation, alkaline phosphatase
and collagen synthesis was evaluated in the presence or not of
50 ng/ml IGF-1, whereas signaling was studied with proteins
separated by SDS-PAGE before western blot analysis. We also
used immunoprecipitation followed by western blot analysis to
detect interactions between key IGF-1 signaling elements. IGF-
1 receptor (IGF-1R), Shc, Grb2, insulin receptor substrate
(IRS)-1, and p42/44 mitogen-activated protein kinase (MAPK)
levels were similar in normal and OA Obs in the presence or
absence of IGF-1. After IGF-1 stimulation, the phosphorylation
of IGF-1R in normal and OA Obs was similar; however, the
phosphorylation of IRS-1 was reduced in OA Ob. In addition,
the PI3K pathway was activated similarly in normal and OA Obs
while that for p42/44 MAPK was higher in OA Obs compared
to normal. p42/44 MAPK can be triggered via an IRS-1/Syp or
Grb2/Shc interaction. Interestingly, Syp was poorly
phosphorylated under basal conditions in normal Obs and was
rapidly phosphorylated upon IGF-1 stimulation, yet Syp showed
a poor interaction with IRS-1. In contrast, Syp was highly
phosphorylated in OA Obs and its interaction with IRS-1 was
very strong initially, yet rapidly dropped with IGF-1 treatments.
The interaction of Grb2 with IRS-1 progressively increased in
response to IGF-1 in OA Obs whereas this was absent in
normal Ob. IGF-1 stimulation altered alkaline phosphatase in
Ob, an effect reduced in the presence of PD98059, an inhibitor
of p42/44 MAPK signaling, whereas neither IGF-1 nor
PD98059 had any significant effect on collagen synthesis. In
contrast, cell proliferation was higher in OA Obs compared to
normal under basal conditions, and IGF-1 stimulated more cell
proliferation in OA Obs than in normal Ob, an effect totally
dependent on p42/44 MAPK activiy. The altered response of
OA Obs to IGF-1 may be due to abnormal IGF-1 signaling in
these cells. This is mostly linked with abnormal IRS-1/Syp and
IRS-1/Grb2 interaction in these cells.
Introduction
Osteoarthritis (OA) represents a major cause of disability, par-
ticularly among the aging population; indeed, it is the most
common form of joint disease. OA is a multifactorial disease
characterized by loss of articular cartilage and subchondral
plate thickening [1]. As the loss of articular cartilage is
believed to be the initial event responsible for joint destruction,
numerous investigations have focused their efforts on under-
standing cartilage homeostasis. Therefore, biochemical analy-
sis of the underlying bone tissue has received little attention,
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despite several reports of abnormal subchondral bone metab-
olism in OA.
Radin and coworkers were the first to study subchondral bone
changes in patients with early degenerative joint disease, and
to propose the participation of subchondral bone in the initia-
tion and progression of cartilage damage [2,3]. They pro-
posed that the thickening of the subchondral bone plate,
resulting from repeated healing of microfractures, could be a
key initiation factor in cartilage degradation. Other groups also
reported abnormal cancellous bone collagen metabolism in
OA, demonstrating that type I collagen, the most abundant
bone matrix protein, is abnormal in OA [4,5]. Recently, we
demonstrated that osteoblast (Ob) cells from human subchon-
dral OA bone demonstrate an altered phenotype in vitro. Our
results showed increased alkaline phosphatase activity,
release of osteocalcin, an increased activity of urokinase plas-
minogen activator (uPA) with no changes in plasminogen acti-
vator inhibitor-1 (PAI-1) abundance, and increases in insulin-
like growth factor (IGF)-1 release compared to normal Obs [6-
8]. As IGF-1 production is increased in OA Obs compared to
normal Obs, it is a likely candidate to promote bone remode-
ling and sclerosis in OA. Interestingly, our laboratory also dem-
onstrated the presence of abnormal uPA regulation by IGF-1
in human OA Obs [6]. These results suggest that IGF-1 sign-
aling could be altered in these cells [6]. The increased remod-
eling in OA bone could possibly account for the observation of
hypomineralization of the subchondral bone tissues in estab-
lished OA [9-11]. Not only the bone matrix is altered in OA but
recent studies have demonstrated that a putative factor(s) pro-
duced by OA subchondral bone cells can influence cartilage
metabolism [12]. This could possibly explain why increased
subchondral bone activity can predict cartilage loss [13-15].
After binding of IGF-1 to its specific surface receptor, the IGF-
1 receptor (IGF-1R) kinase undergoes tyrosine phosphoryla-
tion of its α-subunit and kinase activation. This involves the
phosphorylation of tyrosine residues of substrate adaptor pro-
teins, principally the insulin receptor substrate (IRS)-1. Other
targets have also been identified, such as Shc, IRS-2, IRS-3
and IRS-4 and GAB1 [16,17]. These proteins contain insulin/
IGF-1R-specific tyrosine phosphorylation sites responsible for
their association with various SH2 domain-containing down-
stream effector molecules. In the case of IRS-1, these include
binding sites for phosphatidylinositol 3-kinase (PI3K), protein
tyrosine-specific phosphatase Syp, 14.3.3 proteins, and the
small adaptor protein Grb2, which is responsible for the acti-
vation of Ras and the MAPK pathway [18,19].
Thus, as the response to IGF-1 in human OA Obs is abnormal,
we investigated IGF-1 signaling in OA Obs. Data revelead an
abnormal interaction of phospho-Syp with IRS-1, possibly
leading to decreased IRS-1 activity. Moreover, the interaction
of Grb2 with IRS-1 was abnormal in OA Obs, possibly leading
to altered downstream signaling. These data suggest that an
abnormal response to IGF-1 is linked to abnormal intracellular
signaling, affecting multiple pathways in OA osteoblasts.
Materials and methods
Patients and clinical parameters
Subchondral bone was obtained from OA patients who had
undergone total knee replacement surgery. Specifically,
medial tibial plateaus were dissected away from the remaining
cartilage and trabecular bone under sterile conditions as pre-
viously described [6-8,20]. Only the middle portion of the tibial
plateaus was used to separate the subchondral bone plate
specimens. A total of 40 patients (aged 70.8 ± 7.9 years
(mean ± standard deviation (SD)); 18 males, 22 females) clas-
sified as having OA according to recognized American Col-
lege of Rheumatology clinical criteria were included in this
study [21]. None of the patients had received medication that
would interfere with bone metabolism, including corticoster-
oids, for six months before surgery. A total of 16 bone speci-
mens of medial tibial plateaus from normal individuals (aged
61.5 ± 15.6 years (mean ± SD); 9 males, 7 females) were col-
lected at autopsy within 12 h of death. These were used fol-
lowing the establishment that the donors had not been on any
medication that could interfere with bone metabolism or had
any bone metabolic disease. Individuals showing cartilage
deterioration and/or subchondral bone plate sclerosis were
not included in the normal group. All human material was
acquired following a signed agreement by patients undergo-
ing knee surgery or their relatives for the specimens collected
at autopsy following the Centre Hospitalier de l'Université de
Montréal (CHUM) ethical committee guidelines.
Preparation of primary bone cell culture
The subchondral bone plate was dissected away from the
remaining cartilage and trabecular bone under sterile condi-
tions. Isolation of subchondral bone plate and the cell cultures
were prepared as previously described by a collagenase
digestion procedure [6,7,22,23]. At confluence, cells were
passaged once at 25,000 cells/cm2 in 6 well plates and grown
for 5 days in Ham F12/DMEM (Sigma, St-Louis, MO, USA)
containing 10% FBS (Wisent Inc., St Bruno, Quebec, Can-
ada) before specific assays. Under these culture conditions,
Obs expressed bone-specific type I collagen without any con-
taminations with cartilage-specific type II collagen [23]. Con-
ditioning was performed for an additional 24 h in serum free
Ham F12/DMEM media. Confluent cells were incubated or not
with human IGF-1 (50 ng/ml; Peninsula, Belmont, CA, USA)
for different times as specified per individual experiments. In
some experiments, PD98059 (Sigma-Aldrich), an inhibitor of
the MAP-kinase/Erk kinase pathway, was used at a final con-
centration of 10 μM in the presence or absence of IGF-1, and
controls were treated with the vehicle. Supernatants were col-
lected at the end of the incubation and kept at -80°C prior to
assays. Cells were lysed with RIPA buffer (50 mM Tris-HCl pH
7.4, 1% NP-40, 0.5% Na-deoxicholate, 0.1% SDS, 150 mM
NaCl, with the inhibitors 10 μg/ml aprotinin, 10 μg/mlAvailable online http://arthritis-research.com/content/8/6/R177
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leupeptin, 10 μg/ml pepstatin, 10 μg/ml O-phenatroline, 1 mM
Na-orthovanadate, 1 mM dithiothreitol), and kept at -80°C
prior to assays. Protein determination was performed by the
bisinchoninic acid method [24].
Western immunoblotting and immunoprecipitation
The cell lysates were loaded on polyacrylamide gels and sep-
arated by SDS-PAGE under reducing conditions [25]. Load-
ing was adjusted according to the cellular protein
concentration of each specimen and western blotting of actin
was performed to assess similar loading between samples.
The proteins were electrophoretically transfered onto PVDF
western blotting membranes (Boehringer Mannheim, Penz-
berg, Germany). Immunoblotting was performed as described
in the ECL Plus Western blotting detection system's manual
(Amersham Pharmacia Biotech, Baie d'Urfe, Québec, Can-
ada) using a variety of primary and secondary antibodies. Pri-
mary antibodies included: IGF-1R α-subunit (ab-5, 1:10,000
dilution) from NeoMarkers (Fremont, CA, USA); phosphor-
ylated IGF-1R (pY1158, 1:10,000 dilution) from Biosource
International (Camarillo, CA, USA); IRS-1, IRS-2, Grb2 and
PI3K (1:2,000 dilutions) from Upstate Biotechnology (Lake
Placid, NY, USA); phospho IRS-1 (pS307, 1:1,000 dilution)
from Upstate Biotechnology; phosphotyrosine Ab-1 (Clone
PY-20, 1:15,000 dilution) from NeoMarkers; Shc, and Gab1
(1:5,000 dilutions) from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); phosphorylated Shc (Tyr317, 1:10,000 dilu-
tion), protein kinase B (PKB), phosphorylated PKB (Ser473,
1:1,000 dilution), p42/44 and phosphorylated p42/44
(Thr202/Tyr204, 1:5,000 dilutions) from Cell Signaling Tech-
nology (Beverly, MA, USA); Syp from BD Transduction Labo-
ratories (Mississauga, ON, Canada); and actin (1:10,000
dilution) from Sigma-Aldrich. Secondary antibodies included:
goat anti-mouse IgG (1:100,000 dilution) from Pierce (Rock-
fort, IL, USA); rabbit anti-sheep IgG (1:20,000 dilution) and
goat anti-rabbit IgG (1:10,000 dilution) from Upstate Biotech-
nology. The immunoprecipitation was performed with 175 μg
of the solubilized cell extracts incubated with 4 μg of IRS-1 or
0.5 μg of IGF-1R α-subunit (Ab-4) antibody, overnight at 4°C.
The resulting immunoprecipitates were subjected to SDS-
PAGE as described above. Densitometry analysis of western
blot films was performed on a Macintosh Mac OS 9.1 compu-
ter using the public domain NIH Image program developed at
the US National Institutes of Health with the Scion Image 1.63
program [26].
Real-time RT-PCR quantification
Real-time quantification of Bax-α, Bcl2 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA from normal and
OA Obs treated for 6 h with 100 ng/ml IGF-1 was performed
in the GeneAmp 5700 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) with the 2× Quantitect
SYBR Green PCR Master Mix (Qiagen, Mississauga, ON,
Canada) used according to the manufacturer's specifications.
In brief, 100 ng of the cDNA obtained from the RT-PCR reac-
tions were amplified in a total volume of 50 μl consisting of 1×
Master Mix, 0.5 Unit uracil-N-glycosylase (UNG; Epicentre
Technologies, Madison, WI, USA) and the gene-specific prim-
ers added at a final concentration of 200 nM. The specific
primers were: for Bax-α, 5'-GGA TGC GTC CAC CAA GAA
G-3' (sense) and 5'-CAC CAG TTT GCT GGC AAA G-3'
(antisense); and for Bcl2, 5'-GGC ATC TTC TCC TCC CAG
C-3' (sense) and 5'-GAA GGG CGT CAG GTG CA-3' (anti-
sense); these generated fragments of 208 base-pairs (bp) and
202 bp, respectively. To ensure equivalent loading, GAPDH
was amplified using 20 pmol of each of the primers 5'-CAG
AAC ATC ATC CCT GCC TCT-3' (sense) and 5'-GCT TGA
CAA AGT GGT CGT TGAG-3' (antisense) to generate a pre-
dicted amplified sequence of 318 bp [27]. The tubes were first
incubated for 2 minutes at 50°C (UNG reaction), then at 95°C
for 15 minutes (UNG inactivation and polymerase activation)
followed by 40 cycles consisting each of denaturation (94°C
for 15 s), annealing (60°C for 30 s), extension (72°C for 30 s)
and data acquisition (77°C for 15 s) steps. The data were col-
lected and processed with the GeneAmp 5700 SDS software
(Applied Biosystems, Foster City, CA, USA) and given as
threshold cycle (Ct), corresponding to the PCR cycle at which
an increase in reporter fluorescence above baseline signal can
first be detected. Plasmid DNAs containing the target gene
sequences were used to generate the standard curves. When
comparing normal and OA expression levels, the threshold
cycle (Ct) was converted to number of molecules and the val-
ues for each sample calculated as the ratio of the number of
molecules of the target gene/number of molecules of GAPDH.
Phenotypic characterization of human subchondral 
osteoblast cell cultures
Phenotypic features of Obs cultures were determined by eval-
uating 1,25(OH)2D3-dependent (50 nM) alkaline phosphatase
activity and osteocalcin release, and by the production of col-
lagen type 1. Alkaline phosphatase activity was determined on
cell aliquots by substrate hydrolysis using p-nitrophenylphos-
phate, and osteocalcin release was determined in cell super-
natants using an enzyme immunoassay as previously
described [7,20]. Collagen synthesis was determined as the
de novo release of the carboxy-terminal peptide fragment
(CICP) of collagen type 1, reflecting true collagen synthesis.
This fragment was determined using a selective enzyme-linked
immunosorbent assay (ELISA; Quidel Corporation, Ceder-
lane, Hornby, ON, Canada) in conditioned media from conflu-
ent Obs incubated in Ham F12/DMEM media containing 0.5%
BSA. Cellular proliferation was assessed using the bromode-
oxyuridine (BrdU) cell proliferation assay as described in the
system's manual from Calbiochem (San Diego, CA, USA).
Cells were plated at 10,000 cells/cm2 in 96-well plates in Ham
F12/DMEM media containing 10% FBS. After overnight
attachment, cells were serum-starved in Ham F12/DMEM
media containing 0.5% BSA for 24 h prior to stimulation with
or without 50 ng/ml IGF-1 in the presence or absence of 10
μM PD98059 in the same media.Arthritis Research & Therapy    Vol 8 No 6    Massicotte et al.
Page 4 of 12
(page number not for citation purposes)
Statistical analysis
All quantitative data are expressed as mean ± SEM. The data
were analyzed by Student's t-test, and p values < 0.05 were
considered statistically significant.
Results
Phenotypic characteristics of normal and OA 
osteoblasts and response to IGF-1
The phenotypic characteristics of normal and OA Obs were
first determined by the production of alkaline phosphatase and
release of osteocalcin. Values for normal Obs were 575.6 ±
89.4 nmol/mg protein/30 minutes and 141.6 ± 15.5 ng/mg
protein for alkaline phosphatase and osteocalcin, respectively.
These values were increased in OA Obs and reached 1259.2
± 158.0 nmol/mg protein/30 minutes (p < 0.01 versus normal)
and 261.2 ± 23.5 nmol/mg protein (p < 0.005 versus normal)
for alkaline phosphatase and osteocalcin, respectively, as pre-
viously described [6-8]. OA osteoblasts also synthesized
more collagen type I than normal Obs (3254 ± 272 versus
4246 ± 189 for normal and OA, respectively, p < 0.01)
whereas they failed to produce collagen type II as previously
shown [20].
Cell proliferation was higher in OA Obs compared to normal
Obs (p < 0.015), and IGF-1 promoted cell proliferation in both
normal and OA Obs while the effect was more important in OA
Obs than normal Obs (Figure 1). This effect of IGF-1 was
blocked by PD98059, an inhibitor of the MAPK/Erk-kinase
pathway, and cell proliferation rate returned to basal values.
IGF-1 stimulation also increased alkaline phosphatase activity
in both normal and OA Obs. In normal Obs, IGF-1 raised alka-
line phosphatase activity from 504.9 ± 83 nmol/mgprotein/30
minutes to 625.4 ± 36.1 (23.9% increase) whereas this activ-
ity in OA Obs increased from 712.9 ± 154.9 to 1099.4 ±
346.6 nmol/mg protein/30 minutes (44.8% increase). This
effect was blocked by PD98059 in OA Obs (Figure 2). How-
ever, IGF-1 failed to stimulate collagen type I synthesis in both
normal and OA Obs, and PD98059 was without effect on this
parameter (not illustrated). We also evaluated the expression
of Bax-α and Bcl2 to evaluate the apoptotic potential of these
cells [28-30]. Using quantitative RT-PCR we were able to
demonstrate a reduction in the Bax-α to Bcl2 ratio in OA Obs
compared to normal. Indeed, the ratio of Bax-α to Bcl2 was
22.6 ± 3.4 versus 12.2 ± 2.4 relative units in normal (n = 3)
and OA Obs (n = 3), respectively (p < 0.05).
IGF-1R levels and activation are similar in normal and 
osteoarthitis osteoblasts
IGF-1R levels in normal and OA Obs were evaluated by west-
ern immunoblot analysis. As presented in Figure 3a, no signif-
icant difference could be observed between normal (n = 5)
and OA (n = 5) Obs IGF-1R levels under basal conditions. The
phosphorylation of IGF-1R following IGF-1 stimulation was
very rapid and similar in normal (n = 3) and OA (n = 3) Obs
and increased 2.86 ± 0.36 and 2.52 ± 0.06-fold, respectively,
above basal levels after 30 s (Figure 3b), and phosphorylated
Figure 1
Cell proliferation of normal and osteoarthitis (OA) osteoblasts in  response to insulin-like growth factor (IGF)-1 stimulation Cell proliferation of normal and osteoarthitis (OA) osteoblasts in 
response to insulin-like growth factor (IGF)-1 stimulation. Cells were 
plated at 10,000 cells/cm2 in 96-well plates and incubated overnight in 
Ham F12/DMEM media containing 10% FBS. Cells were then serum-
starved for 24 hours in the same media containing 0.5% BSA then 
treated with or without 50 ng/ml IGF-1 in the presence or not of 10 μM 
PD98059 (PD) for 24 hours followed by incubation with bromodeoxyu-
ridine (BrdU) for their last 24 hours of incubation in the same media. 
BrdU incorporation was then evaluated following the manufacturer's 
instructions. Results are expressed as mean OD units ± SEM for three 
normal and four OA osteoblast preparations.
Figure 2
Effect of insulin-like growth factor (IGF)-1 on alkaline phosphatase  activity in osteoarthitis (OA) osteoblasts Effect of insulin-like growth factor (IGF)-1 on alkaline phosphatase 
activity in osteoarthitis (OA) osteoblasts. Cells were grown to conflu-
ence and incubated overnight in serum free medium. Cells were then 
exposed to 50 nM 1,25(OH)2D3 in Ham F12/DMEM media containing 
2% charcoal-treated FBS and in the presence or not of 50 ng/ml IGF-1 
with or without 10 μM PD98059 (PD). Results are expressed as the 
mean ± SEM of control values without IGF-1 for 6 OA osteoblast 
preparations.Available online http://arthritis-research.com/content/8/6/R177
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IGF-1R levels remained similar until 5 minutes of stimulation
with IGF-1 (data not shown).
IRS-1 is underphosphorylated in osteoarthitis 
osteoblasts
Figure 4a shows that IRS-1 levels in normal (n = 4) and OA (n
= 4) Obs were similar. However, the tyrosine phosphorylation
of IRS-1 was significantly altered in OA Obs compared to nor-
mal. Under basal conditions, the tyrosine phosphorylation of
IRS-1 in OA Obs was 4.65 ± 1.24-fold less phosphorylated
than normal (p < 0.05), and after a 5 minute stimulation with
IGF-1, this level was still about 3.52 ± 0.35-fold less phospho-
rylated (p < 0.005; Figure 4b). Serine phosphorylation of IRS-
1 in OA Obs was similar to normal (data not shown). As we
were unable to detect clear levels of IRS-2 in our Obs, we
excluded the possibility that increasing IRS-2 activation could
lead to downregulation of IRS-1 (data not shown). Moreover,
14.3.3 protein, which is known to bind IRS-1 and modulate its
activation, was not significantly different between normal and
OA Obs (data not shown).
p42/44 phosphorylation are upregulated while PI3K/
PKB pathway is unaltered in OA Obs
Since IGF-1 signaling involves the downstream activation of
two different pathways, namely the MAPK and the PI3K path-
ways, we next evaluated if these pathways were altered
similarly to IRS-1. We first looked at the protein levels of p42/
44. Data showed no differences between normal (n = 3) and
OA (n = 4) Obs (Figure 5a). In contrast, the phosphorylation
of p42/44 was different between normal and OA Obs. After a
5 minute IGF-1 treatment, both p42 and p44 phosphorylation
levels in OA Obs were increased by about 1.53 ± 0.15 (p <
0.025) and 2.18 ± 0.37 (p < 0.05) fold, respectively, com-
pared to normal (Figure 5b). This increase in p42/44 phospho-
rylation is consistent with the observation that OA Obs grow
faster than normal Obs (this study and [7]) and show reduced
apoptosis (see above). Phosphorylation of p42/44 was sus-
tained until 15 minutes, when a difference between normal
and OA Obs could still be observed (data not shown). PI3K
protein levels were unaltered between normal (n = 3) and OA
Obs (n = 3) (data not shown). Similarly, PKB protein levels in
normal (n = 3) and OA (n = 3) Obs were similar. Moerover,
although the phosphorylation of PKB was slightly upregulated
in OA (19.2 ± 1.0 relative units, n = 3) compared to normal
(14.1 ± 1.5 relative units, n = 3) after a 5 minute IGF-1 stimu-
lation, this difference did not reach statistical significance.
Shc and Grb-2 protein levels and activation are similar in 
normal and osteoarthitis osteoblasts
As Shc can also be recruited by IGF-1R and activate down-
stream SH2-domain containing proteins, we also evaluated
the activation of this alternative pathway. No differences were
found between total Shc protein levels in normal (n = 4) and
OA Obs (n = 4). The Shc phosphorylation levels were also not
significantly different between normal and OA Obs after a 5
minute IGF-1 stimulation (data not shown). This suggests that
Figure 3
Insulin-like growth factor (IGF)-1 receptor (IGF-1R) levels and activation in normal and osteoarthitis (OA) osteoblasts Insulin-like growth factor (IGF)-1 receptor (IGF-1R) levels and activation in normal and osteoarthitis (OA) osteoblasts. Cells were grown to conflu-
ence and incubated overnight in serum free medium. (a) After cell lysis in RIPA buffer and immunoprecipitation with an anti-IGF-1R α-subunit anti-
body (ab 4), receptor levels were analyzed by western immunoblot with an anti-IGF-1R α-subunit antibody (ab 5). (b) After cell lysis in RIPA buffer, 
tyrosine phosphorylation of the receptor exposed to 50 ng/ml IGF-1 for 5 minutes was analyzed with anti-IGF-1R phosphotyrosine ab (PY-1158). 
Determination of actin was used as the control for loading. Representative data are shown in panel 1 (a,b). Results expressed as arbitrary scanning 
units are presented as the mean ± SEM (panel 2 (a,b)).Arthritis Research & Therapy    Vol 8 No 6    Massicotte et al.
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Figure 4
Insulin receptor substrate (IRS)-1 levels and activation in normal and osteoarthitis (OA) osteoblasts Insulin receptor substrate (IRS)-1 levels and activation in normal and osteoarthitis (OA) osteoblasts. Cells were grown to confluence and incubated 
overnight in serum free medium. Cells were treated with 50 ng/ml insulin-like growth factor (IGF)-1 for 5 minutes. (a) After cell lysis in RIPA buffer 
and immunoprecipitation with anti-IRS-1 antibodies, IRS-1 levels were analyzed by immunoblotting with the same anti-IRS-1 antibody. (b) After cell 
lysis in RIPA buffer and immunoprecipitation with an anti-IRS-1 antibody, phosphorylated IRS-1 levels were analyzed by immunoblotting with an anti-
phosphotyrosine antibody (PY-20). Determination of actin was used as the control for loading. Representative data are shown in panel 1 (a,b). 
Results expressed as arbitrary scanning units are presented as the mean ± SEM (panel 2 (a,b)).
Figure 5
p42/44 levels and activation in normal and osteoarthitis (OA) osteoblasts p42/44 levels and activation in normal and osteoarthitis (OA) osteoblasts. Cells were grown to confluence and incubated overnight in serum free 
medium. Cells were then exposed to 50 ng/ml insulin-like growth factor (IGF)-1 for 5 minutes. (a) After cell lysis in RIPA buffer p42/44 levels were 
visualized by immunoblotting with an anti-p42/44 antibody. (b) After cell lysis in RIPA buffer phosphorylated p42/44 levels were visualized by immu-
noblotting with an anti-phospho p42/44 antibody. Determination of actin was used as the control for loading. Representative data are shown in 
panel 1 (a,b). Results expressed as arbitrary scanning units are presented as the mean ± SEM (panel 2 (a,b)).Available online http://arthritis-research.com/content/8/6/R177
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this pathway was unaltered in OA Obs. We also examined the
levels of the small adaptor protein Grb2. Data illustrated in Fig-
ure 6a showed no difference between normal and OA Obs
under basal conditions. Upon IGF-1 stimulation, Grb2 levels
did not change either. However, as Grb2 can be associated
with either Shc or phosphorylated IRS-1, we next evaluated
the levels of Grb2 associated with the IRS-1 pathway using a
co-immunoprecipitation strategy. As shown in Figure 6b, co-
immunoprecipitation with IRS-1 followed by western blot
detection of Grb2 showed weak Grb2 levels in both normal (n
= 4) and OA (n = 4), although higher levels could be detected
in OA Obs (4.76 ± 1.44-fold increased levels in OA Obs com-
pared to normal, p < 0.05) under basal conditions. Grb2 levels
associated with IRS-1 did not change significantly in normal
Obs in response to 30 s of IGF-1 stimulation while the levels
decreased with a longer incubation in the presence of IGF-1.
In OA Obs, co-immunoprecipitated Grb2 levels increased
slowly in response to IGF-1 stimulation; however, Grb2 levels
reached about a 2.6 ± 0.8-fold increase compared to basal
levels after a 5 minute IGF-1 stimulation (p < 0.03 by ANOVA)
in OA Obs. A significant difference was also noted between
Grb2 levels upon a 5 minute IGF-1 stimulation in OA Obs
compared to normal (p < 0.01).
Abnormal Syp modulation in OA Obs is implicated in 
underphosphorylation of IRS-1
Syp is a phosphatase known to bind IRS-1 and, once phos-
phorylated on its tyrosine residues, modulate its activity. We
first compared Syp levels between normal and OA Obs. As
observed with the other proteins, no differences were noted
for Syp levels between normal (n = 3) and OA Obs (n = 4) as
shown in Figure 7a. Surprisingly, time-dependent Syp phos-
phorylation in response to IGF-1 was clearly different between
normal and OA Obs. As illustrated in Figure 7b, we observed
the expected activation pattern with normal Obs (n = 3) in
response to a 1 minute IGF-1 stimulation, increasing the phos-
phorylation levels of Syp by 2.7 ± 1.0-fold. On the other hand,
in OA Obs (n = 5), basal Syp phosphorylation was already
higher (12.23 ± 3.09 fold, p < 0.025) compared to normal.
After a 1 minute IGF-1 stimulation, Syp phosphorylation in OA
Obs decreased by 11.94 ± 5.93-fold, which reduced the
phosphorylated Syp levels in OA Obs below those in normal
Obs (p < 0.015). To demonstrate the implication of Syp phos-
phatase in the underphosphorylation of IRS-1 in the resting
state, we next performed a series of co-immunoprecipitation
assays to evaluate the interaction of Syp with IRS-1. As shown
in Figure 8a, there was little Syp associated with IRS-1 in the
basal state for normal Obs (n = 4). However, after a 30 s stim-
ulation with IGF-1, there was a marked increased association
of Syp with IRS-1 in normal Obs that returned to near basal
state after 5 minutes. In OA Obs, the initial Syp levels associ-
ated with IRS-1 are higher than normal (approximately four-
fold) and decreased rapidly to near undetectable levels upon
a one minute IGF-1 stimulation (Figure 8b). These results sug-
gest that the low IRS-1 phosphorylation levels observed in
basal OA Obs could result from the increased association and
activation of Syp phosphatase to IRS-1.
Discussion
As an increasing amount of literature is demonstrating the
involvement of bone tissue in the initiation/progression of OA,
a better understanding of this tissue is clearly of utmost impor-
tance to better understand the etiology of this pathology. IGF-
1 is one of the leading growth factors implicated in bone
remodeling [31]. Interestingly, IGF-1 expression is increased
in OA Obs [32] and these cells present an abnormal response
to this growth factor [6,7]. Hence, we wanted to know if this is
related to an alteration of its signaling pathway. We conducted
a series of experiments to evaluate the IGF-1 signaling path-
way in OA Obs and data revealed that the interaction of IRS-
1 with Syp and Grb2 was modified in these cells in response
to IGF-1 stimulation.
IGF-1R levels as well as phosphorylated IGF-1R levels follow-
ing IGF-1 stimulation were similar in normal and OA Obs.
Figure 6
Grb2 levels and co-immunoprecipitation with insulin receptor substrate  (IRS)-1 in normal and osteoarthitis (OA) osteoblasts Grb2 levels and co-immunoprecipitation with insulin receptor substrate 
(IRS)-1 in normal and osteoarthitis (OA) osteoblasts. Cells were grown 
to confluence and incubated overnight in serum free medium. (a) After 
cell lysis in RIPA buffer Grb2 levels were visualized by immunoblotting 
with an anti-Grb2 antibody. The data show a representative immunoblot 
for three normal and three OA osteoblast preparations. (b) In another 
set of experiments, cells were exposed to 50 ng/ml insulin-like growth 
factor (IGF)-1 for various length of time or its vehicle, as indicated. After 
cell lysis in RIPA buffer and immunoprecipitation with an anti-IRS-1 anti-
body, co-immunoprecipitated Grb2 levels were visualized by immunob-
lotting with an anti-Grb2 antibody. A representative immunoblotting of 
four different experiments is presented. Determination of actin was 
used as the control for loading.Arthritis Research & Therapy    Vol 8 No 6    Massicotte et al.
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Figure 7
Syp activation in normal and osteoarthitis (OA) osteoblasts Syp activation in normal and osteoarthitis (OA) osteoblasts. Cells were grown to confluence and incubated overnight in serum free medium. Cells 
were then exposed to 50 ng/ml insulin-like growth factor (IGF)-1 for 5 minutes. (a) After cell lysis in RIPA buffer Syp levels were visualized by immu-
noblotting with an anti-Syp antibody. (b) After cell lysis in RIPA buffer and immunoprecipitation with an anti-phosphotyrosine antibody (PY-20), phos-
phorylated Syp levels were visualized by immunoblotting with an anti-Syp antibody. Determination of actin was used as the control for loading. 
Representative data are shown in panel 1 (a,b). Results expressed as arbitrary scanning units are presented as the mean ± SEM (panel 2 (a,b)).
Figure 8
Co-immunoprecipitation (Co IP) of Syp with insulin receptor substrate (IRS)-1 in normal and osteoarthitis (OA) osteoblasts Co-immunoprecipitation (Co IP) of Syp with insulin receptor substrate (IRS)-1 in normal and osteoarthitis (OA) osteoblasts. Cells were grown to 
confluence and incubated overnight in serum free medium. Cells were then exposed to 50 ng/ml insulin-like growth factor (IGF)-1 for various lengths 
of time, as indicated. After cell lysis in RIPA buffer and IP with an anti-IRS-1 antibody, co-immunoprecipitated Syp levels were visualized by immuno-
blotting with an anti-Syp antibody. A representative immunoblotting of three different experiments is presented. Determination of actin was used as 
the control for loading.Available online http://arthritis-research.com/content/8/6/R177
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However, IRS-1, the major IGF-1R docking protein, presented
a reduced phosphorylation level in OA Obs, albeit the total
protein level was similar between normal and OA Obs. In con-
trast, the IGF-1R docking protein Shc had similar protein and
phosphorylation levels in normal and OA Obs. As IRS-1 was
the only IGF-1R docking protein showing an abnormal modu-
lation in OA Obs, we pursued our investigation with this factor
and looked for molecules that could regulate IRS-1
phosphorylation.
First, 14.3.3 protein, which is known to bind IRS-1 and modu-
late its activation [19], was not significantly different between
normal and OA Obs, and thus is unable to explain the
underphosphorylation of IRS-1 in OA. Second, as the phos-
phorylation of both Shc and IRS-1 is linked to IGF-1R kinase
activation and the phosphorylation of Shc was similar between
normal and OA Obs, we can not conclude that an abnormal
IGF-1R kinase activation explains the reduced phosphoryla-
tion of IRS-1. Third, we looked for phosphatases able to mod-
ulate IRS-1 activity. The best characterized phosphatase that
binds to and modulates IRS-1 is Syp (or SHP-2) [33]. Syp pro-
tein levels were unaltered between normal and OA Obs. In
contrast, its phosphorylation levels clearly demonstrated
abnormal regulation in OA Obs. Indeed, OA Obs showed
increased basal phosphorylation levels compared to normal,
which was followed with a rapid decrease upon IGF-1 stimu-
lation, in contrast to the situation for normal Obs. Moreover,
the co-immunoprecipitation of Syp/IRS-1 also demonstrated
an increased interaction in the basal state between IRS-1 and
Syp in OA Obs, unlike in normal cells. Since there is an
increase in IGF-1 production in OA Obs with a concomitant
decrease of the major insulin-like growth factor binding pro-
teins, namely BP-3, BP-4 and BP-5, OA Obs are likely to be
more chronically stimulated by IGF-1 than normal Obs [32].
This suggests that the dowregulation of IRS-1 in OA Obs, the
major IGF-1 signaling pathway, is a feedback response to
increased exposure to elevated endogenous IGF-1 levels.
The observed increase in ERK1/2 phosphorylation, while there
was no significant increase in PI3K activity measured by Akt/
PKB phosphorylation, should promote an increase in cell pro-
liferation. In this respect, it is noteworthy that primary OA Ob
cell cultures grow faster than normal Obs [7], and we
observed a reduction of the ratio of expression of Bax-α in OA
Obs compared to normal. As Bax-α promotes apoptosis, a
reduction in the Bax-α/Bcl2 ratio suggests an inhibition of
apoptosis in OA Obs [30]. In the present study we also
observed that OA Obs can grow faster than normal Obs and
that they respond to IGF-1 stimulation with a greater cellular
proliferation rate. This response to IGF-1 was strictly ERK1/2
dependent since PD98059 was able to fully inhibit the effect
of IGF-1 on OA Obs. Such a situation could then lead to more
cells being available and prolonged cell life that would possi-
bly lead to the laying down of more extracellular matrix, as
reported in OA subchondral bone tissue [4,5]. This also
agrees with the recent demonstration that Obs from OA
patients show enhanced proliferation and collagen type I
expression in vitro compared to normal Obs [34]. However,
addition of exogenous IGF-1 to OA Obs failed to increase col-
lagen type I levels, which are already higher in these cells than
normal. In contrast, as IGF-1 promoted alkaline phosphatase
production by Obs, it is noteworthy that it stimulated this activ-
ity better in OA Obs than in normal Obs, and that this was also
dependent on ERK1/2 activity. Similar observations were pre-
viously reported for both activities in Ob-like cells [35] and for
cell proliferation alone in mesangial cells [36]. Overall, these
data would then suggest that the activation of the ERK1/2
pathway in OA Obs in response to IGF-1 is important for cell
proliferation, retards apoptosis and affects alkaline phos-
phatase. This could also promote the production of collagen
type I overall as more cells would synthesize it, resulting in
more collagen being laid down in vivo, although we could not
show that more collagen was produced per cell in vitro in
response to IGF-1. This is reminiscent of observations made in
other tissues where IGF-1 alone could not promote collagen
type I production but, in combination with other growth factors
or high glucose levels, could do so [35-39].
One important question remains: if the main IGF-1R signaling
pathway is dowregulated in OA Obs, how can we explain the
increase in subchondral bone remodeling in OA bone tissue?
Maybe the IGF-1 pathway is not implicated in this process.
However, this seems unlikely since IGF-1 is a key regulator of
bone remodeling and it increases uPA activity in OA Obs [6].
Once stimulated, the tyrosine kinase activity of IGF-1R leads
to its autophosphorylation as well as the phosphorylation of a
number of intracellular proteins, such as IRS-1, Shc and
Gab1. This gives rise to the activation of Ras and PI3K, thus
resulting in the activation of MAPK and PKB [40]. In our dis-
eased cells, PI3K, MAPK and PKB protein levels were similar
to normal, and we detected no significant increase in the acti-
vation of PKB while we observed a clear stimulation of the
MAPK pathway. This implies the possibility of some comple-
mentary pathways for PKB activation that compensate for the
lack of activation via IRS-1 in OA Obs. We recently demon-
strated that transforming growth factor (TGF)-β production is
increased in OA Obs [20] and, since this growth factor can
activate PKB in arthritis, TGF-β stimulation could be one such
compensatory mechanism activating PKB. Interestingly, IGF-1
dependent p42/44 stimulation was significantly increased in
OA Obs. Since the activation of the Ras/MAPK pathway can
modulate the production of uPA following growth factor stim-
ulation, a situation we already observed in OA Obs [7], this
suggests that the increased remodeling observed in OA
subchondral bone could result from the upregulation of the
p42/44 pathway following IGF-1 stimulation [41].
Increased activation of the p42/44 pathway concomitant with
the dowregulation of IRS-1 in OA Obs may seem contradic-
tory. One possible mechanism could be competition betweenArthritis Research & Therapy    Vol 8 No 6    Massicotte et al.
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IRS-1 and Shc for Grb2 [17]. In this model, IRS-1 and Shc
compete for a limited cellular pool of Grb2, and the activation
of the MAPK pathway would predominantly occur through the
Shc-Grb2 signaling pathway. Grb2 is a small adaptor protein
that can associate with IRS-1 and Shc via its SH2 domain and
with the guanylnucleotide exchange factor for Ras, termed
Son of Sevenless (SOS) via its SH3 domain. The association
of the Grb2-SOS complex with tyrosine phosphorylated
receptors and/or Shc have been directly implicated in the acti-
vation of the Ras signaling pathway. Since in OA Obs Grb2
levels were similar to normal, the downregulation of IRS-1
phosphorylation following IGF-1 stimulation in these diseased
cells may result in an increased availability of Grb2 to the Shc
pathway, leading to increased activity of the p42/44 pathway.
However, as shown here, the interaction of Grb2 with IRS-1
was also increased in OA Obs, implying that the Grb2-Shc
interaction should be reduced in these cells. On the other
hand, the p42/44 kinase activity could also be activated
directly by TGF-β via the Smad3 signaling pathway, as previ-
ously proposed by Sowa and colleagues [42], a situation that
overules Grb2-Shc signaling. Indeed, as OA Obs have ele-
vated TGF-β levels [20], this could directly activate the p42/
44 pathway without the involvement of Grb2. Thus, the
elevated endogenous TGF-β levels in OA Obs could then
explain both the results for the PKB and p42/44 pathways
observed here.
Taken together, these results could be interpreted as a general
downregulation of the IGF-1R/IRS-1 pathways in OA Obs.
However, dowstream signals were not actually reduced. The
observed increase in Syp/IRS-1 interaction and increased Syp
phosphorylation could actually promote IGF-1 signaling. A
functional and highly phosphorylated SHP-2/Syp is necessary
for sustained activation of ERK1/2 response to hepatocyte
growth factor (HGF) stimulation in Madin-Darby canine kidney
(MDCK) cells [43] and in rat fibroblasts in response to insulin,
IGF-1 or epidermal growth factor [44]. Moreover, inactivating
Syp antibodies [44] or expression of a mutant phosphatase
[45] significantly reduces insulin, IGF-1 and epidermal growth
factor signaling. Accordingly, as OA Obs showed high phos-
phorylated Syp levels and strong interaction with IRS-1, both
under basal conditions and after IGF-1 stimulation, this could
promote p42/44 activity in OA Obs, as observed in those
studies. Moreover, a recent study indicated that functionally
deficient SHP-1 mice are markedly glucose tolerant and insu-
lin sensitive as a result of enhanced insulin receptor signaling
to IRS-1 [46], which suggests that elevated activity of SHP-1/
Syp could reduce IGF-1 signaling to IRS-1, as observed in the
present study. This would also suggest that, although IGF-1R-
dependent IRS-1 phosphorylation is reduced in OA Obs, Syp
phosphorylation and activity could compensate for this reduc-
tion. As Syp is central to other growth factors, such as HGF
and epidermal growth factor [43,44], and since we recently
showed a key role for HGF in OA Obs [47] and possibly for
the cross-talk between OA Obs and cartilage tissue [48], the
present results suggest that the HGF-dependent pathway
could also be altered in OA Obs, a situation not investigated
at present.
Conclusion
This is the first study demonstrating abnormal IGF-1 cell sign-
aling in human OA subchondral Obs that could explain the
abnormal response of these cells to this growth factor. We
demonstrated an altered IGF-1 pathway involving IRS-1 and
Syp. Moreover, we also demonstrated increased MAPK activ-
ity in IGF-1 stimulated OA Obs, which could be implicated in
the abnormal subchondral bone remodeling observed in OA.
Since both Syp and Grb2 play key roles in the signaling path-
ways of other growth factors in Obs besides IGF-1, this may
also suggest an abnormal response to these growth factors in
OA Obs.
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